Therapeutic effect of surgical debulking of metastatic lymphnode in cervical cancer stage IIICr: A phase III, randomizedcontrolled clinical trial - DEBULK TRIA

Korean Gynecologic Oncology Group0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•(1) Women =20 years and = 70 years of age
•1) Newly diagnosed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
•2) When the radiology examinations such as CT, MRI, or PET-CT show the short-axis of the pelvic
•LN or paraaortic LN under the renal vein is = 2cm, or 3 or more LNs with a short axis = 1 cm
•3) When CCRT is planned as a treatment for cervical cancer
•4) A patient whose competency is ECOG performance score 0-1
•5) A patient which has signed the approved informed consent form for study subjects
•6) A patient for which it is determined that surgical debulking is possible for LN metastasis as
•confirmed by radiological examination

•(1) A patient who has been diagnosed with cancer of any organ other than
•thyroid cancer (excluding stage 0 cancer) within the previous 5 years
•(2) A patient that is pregnant or plans to become pregnant during the clinical
•study period
•(3) A patient with any active infectious disease or incurable severe
•inflammation.
•(4) When surgery is not possible due to internal or surgical disease
•(5) When chemotherapy is impossible due to internal or surgical disease
•(6) A patient with a history of pelvic radiation therapy
•(7) A patient with a history of subtotal hysterectomy
•(7)A patient with a remote metastasis (e.g., lung, supraclavicular lymph node,inguinal lymph node, etc.) other than a pelvic lymph node or paraaortic lymph node metastasis

发起方

Korean Gynecologic Oncology Group